Panthera is delighted to announce that we have joined the Association of Multisite Research Corporations (AMRC), the premier trade association dedicated to advancing the benefits of working with multisite clinical research corporations.
Founded in 2024, AMRC was established to champion the multisite clinical research model and to ensure that sponsors, CROs, policymakers, and regulators fully understand its advantages. It serves as a critical interface between multisite networks, pharmaceutical companies, CROs, and regulators, ensuring the unique capabilities of large multisite organisations are recognised and effectively leveraged.
Membership strengthens Panthera’s ability to collaborate across the industry, contribute to collective advocacy, and help shape the future of clinical research.
Stuart Young, CEO of Panthera, said “We’re proud to be joining the Association of Multisite Research Corporations (AMRC) at a time when sponsors are increasingly looking for deeper, more strategic partnerships with research sites. Multisite organisations now play a critical role in defining what good looks like in clinical trial delivery – not just in speed or scale, but in consistent, measurable quality across geographies. At Panthera, we see quality as something that must be designed, embedded and delivered in the same way, every time, wherever a trial is run. AMRC brings together organisations that share a commitment to working alongside sponsors to raise standards, improve predictability and deliver clinical trials at scale with confidence. We’re pleased to be part of that community and to contribute to shaping how quality is defined and delivered globally.”
By joining AMRC, Panthera reinforces its commitment to innovation, operational excellence, and collaboration – delivering greater value to sponsors and partners while supporting the advancement of high-quality clinical research worldwide.